Everyday Health on MSN
Teprotumumab for moderate to severe thyroid eye disease
Learn about teprotumumab for moderate to severe thyroid eye disease, its benefits, risks, as well as evolving treatment ...
The U.S. Food and Drug Administration has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED).
Reports of cases detail the development of thyroid eye disease 3-5 years following treatment of MS with immunomodulatory ...
On June 26, 2026, Viridian Therapeutics announced that the U.S. Food and Drug Administration (“FDA”) approved LUMVOA™ (veligrotug-vvze) for ...
Local ocular measures and lifestyle changes form the basis of the general management of TED, regardless of severity. Corneal exposure and dry eye symptoms can be prevented or managed with lubricant ...
The success of teprotumumab has demonstrated the potential for insulin-like growth factor-1 receptor (IGF-1R) targeted therapy, and several other agents that target IGF-1R are in various stages of ...
The first half of 2026 brought a steady drumbeat of regulatory and clinical news across the diabetic eye disease space, from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results